Sort by
Items per page

Send to

Choose Destination

Search results

Items: 6


Concurrent Inhibition of Pim and FLT3 Kinases Enhances Apoptosis of FLT3-ITD Acute Myeloid Leukemia Cells through Increased Mcl-1 Proteasomal Degradation.

Kapoor S, Natarajan K, Baldwin PR, Doshi KA, Lapidus RG, Mathias TJ, Scarpa M, Trotta R, Davila E, Kraus M, Huszar D, Tron AE, Perrotti D, Baer MR.

Clin Cancer Res. 2018 Jan 1;24(1):234-247. doi: 10.1158/1078-0432.CCR-17-1629. Epub 2017 Oct 26.


Pim kinase inhibition sensitizes FLT3-ITD acute myeloid leukemia cells to topoisomerase 2 inhibitors through increased DNA damage and oxidative stress.

Doshi KA, Trotta R, Natarajan K, Rassool FV, Tron AE, Huszar D, Perrotti D, Baer MR.

Oncotarget. 2016 Jul 26;7(30):48280-48295. doi: 10.18632/oncotarget.10209.


Uncovering low-dimensional, miR-based signatures of acute myeloid and lymphoblastic leukemias with a machine-learning-driven network approach.

Candia J, Cherukuri S, Guo Y, Doshi KA, Banavar JR, Civin CI, Losert W.

Converg Sci Phys Oncol. 2015 Dec;1(2). pii: 025002. Epub 2015 Dec 21.


The FLT3 and PDGFR inhibitor crenolanib is a substrate of the multidrug resistance protein ABCB1 but does not inhibit transport function at pharmacologically relevant concentrations.

Mathias TJ, Natarajan K, Shukla S, Doshi KA, Singh ZN, Ambudkar SV, Baer MR.

Invest New Drugs. 2015 Apr;33(2):300-9. doi: 10.1007/s10637-015-0205-y. Epub 2015 Jan 20.


Phytochemical evaluation of the wild and cultivated varieties of Eranda Mula (Roots of Ricinus communis Linn.).

Doshi KA, Acharya R, Shukla VJ, Kalyani R, Khanpara K.

Ayu. 2013 Apr;34(2):200-3. doi: 10.4103/0974-8520.119679.


Availability of cord blood extends allogeneic hematopoietic stem cell transplant access to racial and ethnic minorities.

Barker JN, Byam CE, Kernan NA, Lee SS, Hawke RM, Doshi KA, Wells DS, Heller G, Papadopoulos EB, Scaradavou A, Young JW, van den Brink MR.

Biol Blood Marrow Transplant. 2010 Nov;16(11):1541-8. doi: 10.1016/j.bbmt.2010.08.011. Epub 2010 Aug 25.

Supplemental Content

Loading ...
Support Center